Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
Authors
Keywords
-
Journal
OSTEOPOROSIS INTERNATIONAL
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-01-05
DOI
10.1007/s00198-022-06648-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaw – 2022 Update
- (2022) Salvatore L. Ruggiero et al. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
- COVID pandemic and denosumab adherence
- (2022) S. Minisola et al. OSTEOPOROSIS INTERNATIONAL
- Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis
- (2022) Namki Hong et al. CALCIFIED TISSUE INTERNATIONAL
- Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
- (2021) Athanasios D. Anastasilakis et al. Journal of Clinical Medicine
- Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA‐HD Study Extension
- (2021) Sabashini K Ramchand et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases
- (2021) Peter Burckhardt et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2‐Year Randomized Study
- (2021) Anne Sophie Sølling et al. JOURNAL OF BONE AND MINERAL RESEARCH
- The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation
- (2021) Polyzois Makras et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence
- (2021) Giorgia Grassi et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains
- (2020) Judith Everts‐Graber et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial
- (2020) Anne Sophie Sølling et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Osteoporosis Management in the Era of COVID ‐19
- (2020) Elaine W Yu et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis
- (2020) Kosuke Ebina et al. Modern Rheumatology
- Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment
- (2020) Hideomi Kondo et al. JOURNAL OF BONE AND MINERAL METABOLISM
- The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis
- (2020) Polyzois Makras et al. BONE
- Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS
- (2020) Elena Tsourdi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study
- (2020) J. Everts-Graber et al. BONE
- Stopping Denosumab
- (2019) Olivier Lamy et al. Current Osteoporosis Reports
- Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women
- (2019) A. Fassio et al. BONE
- Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐year Clinical Trial
- (2019) Athanasios D. Anastasilakis et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Bone Mineral Density After Transitioning From Denosumab to Alendronate
- (2019) David Kendler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider
- (2019) Liana Tripto-Shkolnik et al. BONE
- Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis
- (2018) Albrecht Werner Popp et al. CALCIFIED TISSUE INTERNATIONAL
- Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates
- (2018) Anne M. Horne et al. CALCIFIED TISSUE INTERNATIONAL
- Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates
- (2018) Liana Tripto-Shkolnik et al. CALCIFIED TISSUE INTERNATIONAL
- Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density
- (2018) K. E. Naylor et al. OSTEOPOROSIS INTERNATIONAL
- One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study
- (2018) E Michael Lewiecki et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
- (2017) Steven R Cummings et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
- (2017) Athanasios D Anastasilakis et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
- (2017) T. Lehmann et al. OSTEOPOROSIS INTERNATIONAL
- Observations following discontinuation of long-term denosumab therapy
- (2017) M. R. McClung et al. OSTEOPOROSIS INTERNATIONAL
- Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study
- (2017) M. B. Zanchetta et al. OSTEOPOROSIS INTERNATIONAL
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
- (2017) Henry G Bone et al. Lancet Diabetes & Endocrinology
- Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report
- (2016) Olivier Lamy et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports
- (2015) B. Aubry-Rozier et al. OSTEOPOROSIS INTERNATIONAL
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
- (2011) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
- (2011) N. Freemantle et al. OSTEOPOROSIS INTERNATIONAL
- Vertebral fracture assessment using a semiquantitative technique
- (2010) Harry K. Genant et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy
- (2009) David L Kendler et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now